Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antipyrine + benzocaine is a combination otic (ear) medication used primarily to relieve ear pain and swelling associated with middle ear infections (acute otitis media), as well as to facilitate the removal of excessive or impacted ear wax (cerumen). Antipyrine acts as an analgesic and anti-inflammatory agent by reducing pain and inflammation in the ear. Benzocaine is a local anesthetic that numbs the area to further alleviate discomfort. The combination may be used alongside antibiotics for infection management. This product is typically formulated as an otic solution for administration directly into the external auditory canal[1][2][3][4][5]. The FDA mandated discontinuation of unapproved prescription versions of this drug in 2015 due to regulatory concerns about safety and manufacturing standards; however, it may still be available in some markets or compounded formulations[5]. Some branded products have been reformulated or discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Antipyrine + benzocaine.